*ST Dapha (603963.SH): As of July 10th, 2024, the company has 16,811 shareholders.

On July 16th, Gelunhui reported that Special Treat Da Yao (603963.SH) stated on the investor interaction platform that the company has not received any relevant notice of changes in shareholding from major shareholders so far. If there are corresponding situations, the company will strictly fulfill its information disclosure obligations in a timely manner according to relevant regulations. As of July 10, 2024, there were 16,811 shareholders of the company.

Gelonghui FinanceJul 16 06:42 ET

Announcement of Dali Pharmaceutical Co., Ltd.'s anticipated half-year performance loss for 2024.

Sensex a shareJul 12 12:00 ET · Announcements

ST Daphar (603963.SH) is expected to lose 11-14 million yuan in the first half of the year.

On July 12th, Gelunhui reported that *ST Deyaoyao (603963.SH) announced a pre-loss notice for its 2024 interim performance. According to preliminary calculations by the financial department, the net income attributable to the owner of the parent company for the first half of 2024 is expected to be between -14 million yuan and -11 million yuan, and compared with the same period of the previous year (legally disclosed data), the loss will increase from 3.2176 million yuan to 0.2176 million yuan. It is expected that the net income attributable to the owner of the parent company after deducting non-recurring gains and losses in the first half of 2024 will be -16 million yuan to -13 million yuan.

Gelonghui FinanceJul 12 05:36 ET

*Special Treat Da Yao (603963.SH): Currently has no medicinal plant cultivation base.

On July 10th, Gelunhui reported that ST Deyao (603963.SH) stated on the investor interaction platform that the company currently does not have any medicinal herb planting bases.

Gelonghui FinanceJul 9 12:12 ET

*ST Pharmaceutical (603963.SH): As of April 19, 2024, the number of shareholders of the company was 33,375

Gelonghui, April 30丨*ST Pharmaceutical (603963.SH) said on an interactive platform that as of April 19, 2024, the number of shareholders of the company was 33,375.

Gelonghui FinanceApr 30 05:48 ET

Dali Pharmaceutical (603963.SH) announced 2023 annual results with a net loss of 2003 million yuan

According to the Zhitong Finance App, Dali Pharmaceutical (603963.SH) disclosed its 2023 annual report. The company achieved revenue of 87.27 million yuan during the reporting period, a year-on-year decrease of 34.06%. The net loss attributable to shareholders of the listed company was RMB 200314 million, and the net loss attributable to shareholders of the listed company after deducting non-recurring profit and loss was RMB 25.22,900.

Zhitong FinanceApr 25 06:38 ET